Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8071415 | 0.83 | L3MBTL1 (0.42) | L3MBTL1CES2CES1 | |
| SCHEMBL1833474 | 0.83 | L3MBTL1 (0.42) | L3MBTL1CES2CES1 | |
| SCHEMBL30640891 | 0.83 | L3MBTL1 (0.42) | L3MBTL1CES2CES1 | |
| SCHEMBL4718081 | 0.83 | L3MBTL1 (0.42) | L3MBTL1CES2CES1 | |
| Hydrochloric Acid SCHEMBL1833471 | 0.82 | L3MBTL1 (0.41) | L3MBTL1CES2CES1 | |
| Hydrochloric Acid SCHEMBL1833472 | 0.82 | L3MBTL1 (0.41) | L3MBTL1CES2CES1 | |
| SCHEMBL28026688 | 0.81 | L3MBTL1 (0.50) | L3MBTL1MEN1KMT2ACES2CES1 | |
| SCHEMBL5021047 | 0.79 | ACKR3 (0.48) | L3MBTL1MEN1KMT2ACES2CES1 | |
| SCHEMBL14542094 | 0.79 | L3MBTL1 (0.40) | L3MBTL1MEN1KMT2ACES2CES1 | |
| SCHEMBL13390925 | 0.79 | ACKR3 (0.48) | L3MBTL1MEN1KMT2ACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262227-A1 | PROCESS FOR MAKING RISPERIDONE AND INTERMEDIATES THEREFOR | SLANINA PAVEL | 2008-10-23 | — | — | US | disclosed |
| US-20080262227-A1 | PROCESS FOR MAKING RISPERIDONE AND INTERMEDIATES THEREFOR | SLANINA PAVEL | 2008-10-23 | — | — | US | disclosed |
| US-7405298-B2 | Process for making risperidone and intermediates therefor | SYNTHON IP INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405298-B2 | Process for making risperidone and intermediates therefor | SYNTHON IP INC. (US) | 2008-07-29 | — | — | US | disclosed |
| WO-2004043923-A1 | PROCESS FOR MAKING RISPERIDONE AND INTERMEDIATES THEREFOR | SYNTHON B.V. (NL) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262227-A1 | PROCESS FOR MAKING RISPERIDONE AND INTERMEDIATES THEREFOR | FAR1, HSD17B11, CYP4Z1 | L3MBTL1 3715/4885MEN1 4076/4885KMT2A 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.